Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Bielosludtsev, K. Bielosludtseva, O. Nazarenko (Dnipropetrovsk, Ukraine). Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP). Eur Respir J 2013; 42: Suppl. 57, 2714

Member's Comments

No comment yet.

Related content which might interest you: C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008 C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)? Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Does the serum C-reactive protein (CRP) predict adverse outcomes in patients admitted with community acquired pneumonia? Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Diagnostic accuracy of lipopolysaccharide-binding protein (LBP), fibrinogen and C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 C-reactive protein (CRP), an early prognostic tool in community acquired pneumonia (CAP) Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia? Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021 The prognostic value of consecutive C-reactive protein measurements in community acquired pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009